Partial Sciatic Nerve Ligation (PSNL) Model Development Service

Are you currently facing long drug development cycles or a lack of reliable preclinical models for your pain research? Our partial sciatic nerve ligation (PSNL) models development service helps you accelerate drug discovery and validate novel analgesic compounds through a robust and clinically relevant in vivo platform. We provide a gold-standard model for studying chronic neuropathic pain, enabling you to make informed decisions faster.

Neuropathic pain is a complex condition with a pressing need for effective therapies. The PSNL model is a highly regarded preclinical tool that closely mimics the etiology and symptoms of clinical neuropathies. It is a cornerstone of modern pain research, enabling the investigation of pain mechanisms and the evaluation of new drugs. The model's ability to induce a long-lasting and reproducible pain phenotype is a key reason for its widespread use and credibility, as supported by decades of published literature.

How Our PSNL Models Development Service Can Assist Your Project

Our service provides a comprehensive solution for researchers seeking to evaluate the efficacy of their therapeutic candidates in a highly predictive animal model of neuropathic pain. We deliver a fully characterized and validated PSNL model, along with a complete suite of behavioral, histological, and molecular analysis services. This end-to-end approach ensures you receive high-quality, reproducible data that is essential for advancing your project.

Discover How We Can Help - Request a Consultation

Workflow

• Required Starting Materials: To initiate a project, we require details on your compound's mechanism of action, desired dosing regimen (e.g., dose, route, frequency), and the specific research questions you aim to answer. Providing these details enables us to design a tailored study protocol that meets your scientific objectives.

• Final Deliverables:
  1. A detailed, publication-ready study report with all methodology and results.
  2. Complete raw data files from all behavioral, histological, and molecular assays.
  3. High-resolution histological images (if applicable) and corresponding analysis.
• Estimated Timeframe: The typical timeframe for a PSNL study ranges from 6 to 10 weeks, depending on the complexity of the study design and the duration of the behavioral observation period.

Why Choose Us?

At Creative Biolabs, our PSNL models development service stands out due to our decades of experience and commitment to scientific excellence. Our standardized protocols ensure minimal variability and maximum reproducibility, providing you with the highest quality data for your drug development program. We offer a level of precision and expertise that accelerates your research timelines and de-risks your preclinical projects.

Experience the Advantage - Get a Quote Today

Customer Reviews

"Using CBL's PSNL models development service in our research has significantly improved the reproducibility of our neuropathic pain studies. The consistency in the model's behavioral phenotype saved us valuable time and resources." (2024), Sa***h F.

"The detailed histological and molecular analysis provided by CBL allowed us to not only confirm our compound's efficacy but also gain deeper insights into its mechanism of action, including glial cell modulation." (2024), D***d T.

"We compared CBL's PSNL service to an in-house model and found their behavioral data to be far more robust and reliable. Their team's expertise in pain assays is evident in the quality of the results we received." (2023), A***a K.

Partial Sciatic Nerve Ligation (PSNL) Models

• What is the PSNL Model?

The PSNL model, first described by Seltzer et al., is a gold-standard preclinical model for inducing and studying chronic neuropathic pain. The model involves the tight ligation of approximately one-third to one-half of the sciatic nerve in the hind leg of a rodent. This partial injury creates a mixed picture of nerve damage and preserved nerve fibers, which more accurately mimics the clinical presentations of complex regional pain syndrome (CRPS) and other forms of traumatic neuropathy.

• Pathophysiological Parallels and Mechanistic Insight

The PSNL injury triggers a complex cascade of molecular and cellular events that mirror human neuropathies. Research utilizing this model has shed light on key molecular players, such as High Mobility Group Box-1 (HMGB1). Studies have shown that HMGB1 is released from injured spinal neurons, where it contributes to microglial and neuronal activity, which in turn drives neuropathic pain symptoms. This makes the PSNL model an ideal platform for exploring these underlying mechanisms and validating novel therapeutic targets that intervene in specific pathways.

• Key Behavioral Endpoints

The resulting condition is characterized by a reliable and long-lasting state of allodynia (pain from non-painful stimuli) and hyperalgesia (increased sensitivity to painful stimuli), as well as persistent pain and changes in limb temperature. These symptoms closely parallel those seen in human patients, making the PSNL model an invaluable tool for translational research and the evaluation of new analgesic drugs.

What We Can Offer

• One-stop-shop for neuropathic pain models: We provide a comprehensive service from precise PSNL model generation to in-depth analysis, streamlining your research workflow.
• Highly reproducible pain models: Our standardized surgical procedures and rigorous quality control ensure consistent behavioral phenotypes, providing a reliable platform for evaluating your therapeutic candidates.
• Customized study design: We work with you to tailor every aspect of the study, from animal species and dosing regimens to the specific behavioral and molecular endpoints, to meet your unique project requirements.
• Advanced data and analysis: Beyond standard behavioral testing, we offer advanced histological and molecular services, including immunohistochemistry for specific markers like HMGB1 and qPCR, to help you uncover the underlying mechanism of action of your compound.
• Expert guidance throughout the process: Our team of experienced scientists provides professional consultation and clear communication at every stage of your project, ensuring your research is on the right track.
• Proven track record: Our published data and successful client case studies demonstrate our ability to deliver high-quality, actionable results that accelerate drug discovery.

Related Services

To further support your neuropathic pain research, we offer a range of complementary services that can be used in conjunction with our PSNL platform:

• Acute Pain Models
• Inflammatory Pain Models
• Biomarker Development & Validation
• Neuroinflammation Studies

To learn more about our PSNL models and how we can support your project, please contact our team of specialists. We are ready to provide detailed information and design a customized study plan to meet your unique needs.

Contact Our Team for More Information and to Discuss Your Project.